AKT1 and prostate carcinoma: The small molecule Akt inhibitor Ipatasertib (GDC-0068) has been examined in phase I trials against breast, ovarian and prostate cancers (NCT03840200, NCT01562275, NCT01362374) (Yan et al., 2013), as well as in phase II trials for gastric cancers (NCT01896531) and in combination with paclitaxel for breast cancer treatment (NCT02301988, NCT02162719).